Compare INBK & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 248.8M |
| IPO Year | 2013 | 2017 |
| Metric | INBK | PROF |
|---|---|---|
| Price | $24.36 | $6.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.00 | $11.14 |
| AVG Volume (30 Days) | 41.1K | ★ 180.6K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 1.10 | N/A |
| Revenue | $11,541,000.00 | ★ $16,098,000.00 |
| Revenue This Year | $18.83 | $61.76 |
| Revenue Next Year | $12.94 | $70.98 |
| P/E Ratio | $22.62 | ★ N/A |
| Revenue Growth | ★ 101.84 | 50.73 |
| 52 Week Low | $18.43 | $4.91 |
| 52 Week High | $31.09 | $8.95 |
| Indicator | INBK | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 43.60 |
| Support Level | $22.96 | $5.30 |
| Resistance Level | $24.67 | $7.19 |
| Average True Range (ATR) | 0.87 | 0.51 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 9.59 | 12.73 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.